May 9, 2024

Brightlobe secures places in Catapult 2022-23 semi-finals

Brightlobe is among six high-potential Ireland-UK start-ups.

Six high-potential Ireland-UK start-ups will join 36 others from across Europe at the semi-finals of the EIT Health Catapult pitching competition 2022-23. Each year, the competition showcases Europe’s most promising biotech, medtech and digital health start-ups to leading experts and investors. Many participants of the competition have gone on to achieve significant growth.

Catapult success stories

In 2021, two winners from the 2020 competition celebrated major acquisitions. Second place in the biotech category, PhagoMed, was acquired by BioNTech and the third-place finalist in digital health, Patchai, was acquired by US-based Alira Health. SparingVision, a 2019 Catapult winner, raised €44.5 million to accelerate the development of their breakthrough treatment tackling chronic ocular diseases in 2020.

The Ireland-UK 2021-22 Catapult finalists included Luminate Medical, SolasCure, Brightlobe, all of which pitched at the EIT Health Summit in Stockholm last month. Luminate Medical has since closed a €5M investment round.

How were the Catapult 2022-23 semi-finalists selected?

Each of the six start-ups selected to progress to the European semi-finals in the 2022-23 competition, passed a comprehensive pre-selection process during the regional finals. Having competed against other top quality biotech, medtech and digital health start-ups, they now have the opportunity to receive individualised training to prepare them for the semi-finals where they will join 36 start-ups from 14 other countries.

Brightlobe Team

This post was written by our award-winning Brightlobe team.

Our Blog

News & Articles

Explore the latest news and articles on how our technology is transforming healthcare through gaming.